Summary:
In women with type 2 diabetes, oral sitagliptin therapy for 52 weeks significantly preserved total proximal femur bone mineral density (BMD) T score compared to placebo treatment, though it was associated with no major adverse events and only mild to moderate side effects equally distributed across groups.
| PICO | Description |
|---|---|
| Population | Women with type 2 diabetes on stable metformin monotherapy and glycemic control, recruited from outpatient clinics in Italy. |
| Intervention | Oral sitagliptin therapy for 52 weeks, evaluated for effects on bone mineral density and bone metabolism. |
| Comparison | Placebo group receiving identical capsules over 52 weeks; both groups continued background metformin therapy. |
| Outcome | Sitagliptin preserved total proximal femur BMD T score (estimated mean difference vs. placebo: 0.11; 95% CI: 0.03–0.19; p = 0.0063). No significant changes were observed in other skeletal sites or bone turnover markers. Sitagliptin also reduced inflammatory markers. No differences in glycemic control or serious adverse events were noted. |
Source: Barchetta, Ilaria, et al. “Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial.” Read article here.
